30.07.2013 Fresenius SE & Co. KGaA  DE0005785604

DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces H1/2013 record results, raises 2013 Group earnings guidance


 
Fresenius SE & Co. KGaA / Key word(s): Quarter Results 30.07.2013 06:59 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius announces H1/2013 record results, raises 2013 Group earnings guidance Group sales increased by 8% (9% in constant currency) to EUR9,987 million (H1/2012: EUR9,236 million). Organic sales growth was 5%. Acquisitions contributed a further 5%. Divestitures reduced sales growth by 1%. Group EBIT* increased by 1% (2% in constant currency) to EUR1,448 million (H1/2012: EUR1,440 million). The EBIT margin of 14.5% (H1/2012: 15.6%) was impacted by a margin decrease at Fresenius Medical Care as well as the first-time consolidation of Fenwal. However, Q2/2013 margin of 14.8% already showed a distinct improvement over Q1/2013 (14.2%). Group net income** increased by 11% (12% in constant currency) to EUR482 million (H1/2012: EUR434 million). Group net income attributable to shareholders of Fresenius SE & Co. KGaA including one-time integration costs for Fenwal was EUR462 million or EUR2.59 per share. Based on the Group's positive growth prospects for the second half of 2013, Fresenius raises its full-year earnings guidance. The company now expects net income*** to increase by 11% to 14% in constant currency. Previously, Fresenius expected net income growth of 7% to 12% in constant currency. The company fully confirms its sales guidance. Sales are expected to increase by 7% to 10% in constant currency. * 2013 excluding Fenwal integration costs (EUR27 million). 2012 excluding one-time costs related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR7 million). ** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding Fenwal integration costs (EUR20 million); 2012 excluding a non-taxable investment gain (EUR34 million) as well as one-time costs related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR26 million). *** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013 excluding Fenwal integration costs  (~EUR 50 million pre tax); 2012 excluding a non-taxable investment gain (EUR34 million) and other one-time costs at Fresenius Medical Care (EUR17 million) as well as one-time costs related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR29 million). (Financial statements according to U.S. GAAP) Fresenius SE & Co. KGaA, represented by Fresenius Management SE, Board of Management Bad Homburg v.d.H., July 30, 2013 End of note 30.07.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius SE & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg v.d.H. Germany Phone: +49 (0)6172 608-2485 Fax: +49 (0)6172 608-2488 E-mail: [email protected] Internet: www.fresenius.com ISIN: DE0005785604 WKN: 578560 Indices: DAX Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard), München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart; Terminbörse EUREX End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 29.083,00 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 39.695,00
EBITDA1,2 5.500,00 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 0,00
EBITDA-Marge3 18,91 18,69 17,04 19,01 19,66 18,27 0,00
EBIT1,4 4.327,00 4.589,00 5.251,00 4.631,00 4.385,00 4.252,00 4.990,00
EBIT-Marge5 14,88 13,69 14,83 12,43 12,09 11,33 12,57
Jahresüberschuss1 2.676,00 1.816,00 1.871,00 1.915,00 2.823,00 1.867,00 2.035,00
Netto-Marge6 9,20 5,42 5,28 5,14 7,78 4,98 5,13
Cashflow1,7 3.574,00 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 5,58
Ergebnis je Aktie8 2,83 3,25 3,37 3,44 3,06 3,26 2,80
Dividende8 0,62 0,75 0,80 0,84 0,88 0,92 0,80
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 24,570 Kaufen 13.838,74
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
8,33 17,30 0,48 8,41
KBV KCV KUV EV/EBITDA
0,75 2,73 0,37 5,58
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,88 0,92 3,74 13.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
04.05.2022 02.08.2022 01.11.2022 24.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-16,22% -26,22% -30,59% -45,86%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei DGAP abrufen


Medtech , 578560 , FRE , XETR:FRE